Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) has been given a $19.00 price objective by equities researchers at Deutsche Bank AG in a research report issued on Monday. The firm currently has a “hold” rating on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s price objective indicates a potential upside of 32.04% from the stock’s current price.

VRX has been the subject of a number of other research reports. J P Morgan Chase & Co set a $10.00 price target on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Monday, July 17th. BTIG Research reiterated a “neutral” rating on shares of Valeant Pharmaceuticals International in a research report on Wednesday, May 10th. BMO Capital Markets reiterated a “market perform” rating on shares of Valeant Pharmaceuticals International in a research report on Wednesday, May 10th. Guggenheim assumed coverage on Valeant Pharmaceuticals International in a research report on Saturday, June 17th. They issued a “buy” rating and a $18.00 price target for the company. Finally, Wells Fargo & Company reiterated an “underperform” rating and issued a $9.00 price target on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 10th. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $17.81.

Shares of Valeant Pharmaceuticals International (VRX) traded down 1.494% on Monday, hitting $14.175. 5,420,293 shares of the stock traded hands. The stock has a 50 day moving average of $16.18 and a 200 day moving average of $13.40. The company’s market cap is $4.94 billion. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $32.75.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The business had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. During the same quarter last year, the company posted ($0.88) EPS. Valeant Pharmaceuticals International’s revenue for the quarter was down 7.7% on a year-over-year basis. Equities analysts anticipate that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International, Inc. (VRX) Given a $19.00 Price Target at Deutsche Bank AG” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/21/valeant-pharmaceuticals-international-inc-vrx-given-a-19-00-price-target-at-deutsche-bank-ag.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Morgan Stanley increased its position in shares of Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock worth $30,631,000 after buying an additional 903,256 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Valeant Pharmaceuticals International by 61.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 41,414 shares of the specialty pharmaceutical company’s stock worth $457,000 after buying an additional 15,719 shares during the last quarter. Gabelli Funds LLC bought a new position in shares of Valeant Pharmaceuticals International during the first quarter worth $331,000. Bogle Investment Management L P DE bought a new position in shares of Valeant Pharmaceuticals International during the first quarter worth $11,223,000. Finally, Guggenheim Capital LLC increased its position in shares of Valeant Pharmaceuticals International by 18.6% in the fourth quarter. Guggenheim Capital LLC now owns 17,540 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 2,752 shares during the last quarter. 50.96% of the stock is currently owned by institutional investors and hedge funds.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.